Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Black Diamond Therapeutics, Inc (NASDAQ:BDTX) Holds Steady: What Could Break the Deadlock?

● Black Diamond Therapeutics is a Cambridge, Massachusetts-based precision-oncology company.

Nitish Kishor | 10 September 2026

Boston Scientific (NYSE: BSX) Faces a 2026 Guidance Hit After Cyberattack Disruption

ACybersecuritybreach has forced one of the largest names in medical devices to warn that it will miss its own financial targets. Boston Scientific Corporation (NYSE: BSX) disclosed that unauthorized network activity disruptedManufacturingand shipping across its global operations, and that the fallout will materially dent …

Nitish Kishor | 10 September 2026

Affimed's Fall From Nasdaq Immuno-Oncology Star to a (OTC:AFMDQ) Penny Quote

Affimed N.V. (OTC:AFMDQ) is a cautionary chapter in immuno-oncology. Once a Nasdaq-listed developer of innate-immunity cancer therapies with a well-followed pipeline, the company's shares have collapsed to a fraction of a cent and now change hands over the counter under a ticker carrying the …

Nitish Kishor | 10 September 2026

AlumiFuel Power's (OTC:AFPW) Hydrogen-From-Aluminum Pitch Has Been Dormant for Years

AlumiFuel Power Corporation (OTC:AFPW) belongs to a quiet corner of the market where once-promising clean-energy stories went dark. The company built its pitch around hydrogen, generating gas and heat by reacting aluminum with water, but its most recent verifiable milestones date back roughly half …

Nitish Kishor | 10 September 2026

Amarantus Bioscience's (OTC:AMBS) Neurology Ambitions Are Worth More Than Its Market Cap

Amarantus BioScience Holdings, Inc (OTC:AMBS) has spent years chasing ambitious ideas across neurology, diagnostics and regenerative medicine, yet its stock tells a starker story. AMBS now changes hands at a fraction of a cent, with aMarket Valuemeasured in the hundreds of dollars and no …

Nitish Kishor | 10 September 2026

Amphastar Pharmaceuticals, Inc (NASDAQ:AMPH) Holds Steady: What Could Break the Deadlock?

● For a profitable, cash-generating pharmaceutical company, share performance tends to track fundamentals and sector sentiment rather than binary news.

Nitish Kishor | 10 September 2026

Anthera Pharmaceuticals (OTC:ANTH) Didn't Survive Its Pivotal Trial Failures

Anthera Pharmaceuticals (OTC:ANTH) belongs to a large graveyard of clinical-stage biotechs whose lead programs failed and whose shares dwindled to almost nothing. Once a Nasdaq-listed developer of treatments for autoimmune and rare diseases, Anthera has left virtually no fresh public footprint for years.

Nitish Kishor | 10 September 2026

Aridis Pharmaceuticals' (OTC:ARDS) Antibody Pipeline Went Quiet After Leaving Nasdaq

Aridis Pharmaceuticals (OTC:ARDS) was once a Nasdaq-listed developer of antibody therapies for serious infectious diseases, but the stock now trades for a fraction of a cent on the over-the-counter market in the last closing session. The company's public disclosure has thinned dramatically, and its …

Nitish Kishor | 10 September 2026

Athersys (OTC:ATHXQ) Has No New Catalyst Because Its Story Already Ended in 2023

Athersys, Inc (OTC:ATHXQ) spent the better part of two decades pursuing an ambitious idea: an off-the-shelf regenerative cell therapy, MultiStem, that could treat conditions ranging from stroke to acute respiratory distress. The science drew genuine interest, but theBusinesscould not outrun its cash needs, and …

Nitish Kishor | 10 September 2026

Nuo Therapeutics, Inc (OTC:AURX) Turns Positive: Why It Belongs on the September 2026 Watchlist

● Interest reflects improving fundamentals and a supportive analyst view rather than a confirmed single-day catalyst.

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…